Regeneron Pharmaceuticals Inc. Faces Class Action Lawsuit

February 02, 2025

Regeneron Pharmaceuticals Inc. (REGN) is currently facing a class action lawsuit filed by investors. The lawsuit alleges that the company made false and misleading statements regarding the efficacy and safety of its flagship drug, leading to substantial financial losses for investors.

The plaintiffs claim that Regeneron misled investors by overstating the success of its drug in clinical trials and failing to disclose important information about potential side effects. The lawsuit also accuses the company of violating federal securities laws by failing to disclose material information to investors.

This class action lawsuit has attracted significant attention in the investment community, as Regeneron Pharmaceuticals Inc. is a major player in the pharmaceutical industry. The outcome of the lawsuit could have a significant impact on the company's reputation and financial standing.

Investors who wish to join the class action lawsuit have until March 10, 2025, to contact Levi Korsinsky, a renowned securities litigation firm. Levi Korsinsky specializes in representing shareholders and has a track record of success in similar cases.

Despite the ongoing lawsuit, it is important to note that this news article does not offer any investment advice or recommendations. Investors are encouraged to seek the advice of professionals, such as Stocks Prognosis, when considering the purchase or sale of Regeneron Pharmaceuticals Inc. stocks.

Find out how the REGENERON PHARMACEUTICALS, INC. rate is expected to change

Get Forecast for REGN

Investor opinions & comments:

I'm curious to see if the allegations against Regeneron are proven true

— from MatthewGarcia at 02-05-2025 10:47

I'm not sure if joining the lawsuit will be worth the effort and potential costs

— from LaylaFloyd at 02-05-2025 08:01

This class action lawsuit could have a significant impact on Regeneron's reputation and financial standing

— from MarketMikayla at 02-04-2025 21:08

Regeneron's reputation and financial standing may be at risk if found guilty

— from MoneyMabel at 02-04-2025 11:33

I want to know more details about the alleged false statements made by Regeneron

— from SavvySusan at 02-03-2025 21:10

I wonder how this will affect Regeneron's stock price in the long run

— from ProfitPam at 02-03-2025 20:49

It's important for investors to seek professional advice before making any decisions regarding Regeneron stocks

— from PennyInvestor at 02-03-2025 02:16

Levi Korsinsky has a good track record, so their involvement in the lawsuit is encouraging

— from AubreyCook at 02-03-2025 00:40

I wonder if other shareholders are joining the class action lawsuit as well

— from WealthyWyatt at 02-02-2025 23:52

If you want to leave a comment, then you need Login or Register

Other news for REGN

May 30, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave's Price Target with 20.42% Profit ~2 min.

In a recent success story for QuantWave, the automated forecasting platform accurately predicted a short position for REGENERON PHARMACEUTICALS, INC....

May 30, 2025REGENERON PHARMACEUTICALS, INC. Stock Hits Price Target Forecast, Bringing 27.31% Profit ~1 min.

On March 4, 2025, QuantWave, the automated forecasting platform, issued a short signal for REGENERON PHARMACEUTICALS, INC. stock when it was trading at $674.49....

May 30, 2025REGENERON PHARMACEUTICALS, INC. Hits 29.73% Profit Target as Forecasted by QuantWave ~1 min.

REGENERON PHARMACEUTICALS, INC. (NASDAQ: REGN) achieved a significant milestone as it hit the price target forecasted by QuantWave, providing investors with a profit of 29.73%....

May 30, 2025REGENERON PHARMACEUTICALS, INC. Hits Short Forecast Target with 17.43% Profit ~1 min.

QuantWave's forecast signal for REGENERON PHARMACEUTICALS, INC. on July 1, 2022, predicted a short direction with a price of $593.76....

May 30, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 21.51% Profit ~1 min.

REGENERON PHARMACEUTICALS, INC. has successfully reached the price target forecast set by QuantWave, resulting in a profitable outcome for investors....

Related news

January 22, 2025Regeneron Pharmaceuticals REGN Faces Securities Class Action After Losing 9 Billion Value Following Q3 2024 Earnings Report ~1 min.

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is facing a securities class action after suffering a massive value loss of 9 billion following their Q3 2024 earnings report....

January 12, 2025Regeneron Pharmaceuticals Faces Shareholder Class Action Lawsuit ~1 min.

Regeneron Pharmaceuticals, Inc., a leading biotechnology company, is currently facing a shareholder class action lawsuit....

February 6, 2025Regeneron Pharmaceuticals Inc. faces legal action for Securities Law Violations - Seek advice from The Gross Law Firm ~2 min.

Regeneron Pharmaceuticals Inc., a leading biotechnology company, is currently facing a lawsuit for alleged violations of securities laws....

January 9, 2025Regeneron Pharmaceuticals REGN Faces Securities Class Action After Losing 9 Billion Value Following Q3 2024 Earnings Report Hagens Berman ~1 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is facing a securities class action after losing $9 billion in value following its Q3 2024 earnings report....

January 29, 2025Novo Nordisk AS Sued for Securities Law Violations - Contact Levi Korsinsky Before March 25, 2025 to Discuss Your Rights - NVO ~1 min.

Novo Nordisk AS, a leading global pharmaceutical company, is facing a lawsuit for alleged securities law violations....

Search on StockPrognosis.com

Sections of the site

Regeneron Pharmaceuticals Inc. Faces Class Action Lawsuit

Find out how the REGENERON PHARMACEUTICALS, INC. rate is expected to change

Investor opinions & comments:

Other news for REGN

Related news

Stocks-Prognosis.com © 2025